ArticleBMC cardiovascular disorders2025
Comprehensive bioinformatic analysis identifies potential therapeutic drugs for CryAB (R120G)-related cardiomyopathy.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lysine Lactylation Modifies Cryab-Hspa1b Interactions and Prevents MAPK Signaling to Slow Diabetic Cardiomyopathy Progression.Diabetes · 2026Article
- Omics approaches to understand cardiovascular disease.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
CryAB, known as Alpha-B Crystallin, has also been shown to bind and increase the unfolding force of the filamentous protein. Mutation of CryAB at R120G causes serious cardiomyopathy but lacks ideal therapeutic drugs. In the present study, we constructed CryAB (R120G)-transgenic (TG) mice. One hundred and four differentially expressed genes (DEGs) in heart tissues of TG mice were screened through RNA sequencing. Gene ontology (GO) and KEGG pathway analyses highlighted enrichment in critical biological processes such as blood circulation regulation, contractile fiber formation, actin binding, thyroid hormone signaling, endocytosis, and alanine, aspartate, and glutamate metabolism. Protein-protein interaction (PPI) analysis pinpointed key hub genes, including DHTKD1, NKTR, SCN5A, CLCN1, RPA1, ACSF2, ACACB, TTC28, HSPA1B. By using Connectivity Map (CMap) analysis and transcriptome data, we identified phosphodiesterase (PDE) family as potential targets and several potential therapeutic candidates, with nortriptyline, torin-1, and cilostazol emerging as top candidates. Molecular docking simulations showed that Nortriptyline exhibited strong binding affinities with hub proteins, particularly SCN5A. These findings suggest promising new therapeutic strategies for CryAB(R120G)-related cardiomyopathy by targeting specific pathways and hub genes to mitigate cardiac dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.